Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $689.9 million.

  • Catalyst Pharmaceuticals' Cash & Equivalents rose 5596.74% to $689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $689.9 million, marking a year-over-year increase of 5596.74%. This contributed to the annual value of $517.6 million for FY2024, which is 27603.03% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Cash & Equivalents of $689.9 million as of Q3 2025, which was up 5596.74% from $652.8 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Cash & Equivalents peaked at $689.9 million during Q3 2025, and registered a low of $121.0 million during Q3 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $210.9 million (2022), whereas its average is $299.3 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Cash & Equivalents crashed by 5387.46% in 2023 and then surged by 27603.03% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Cash & Equivalents stood at $171.4 million in 2021, then soared by 74.05% to $298.4 million in 2022, then plummeted by 53.87% to $137.6 million in 2023, then skyrocketed by 276.03% to $517.6 million in 2024, then skyrocketed by 33.3% to $689.9 million in 2025.
  • Its Cash & Equivalents stands at $689.9 million for Q3 2025, versus $652.8 million for Q2 2025 and $580.7 million for Q1 2025.